Clinical Study
Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
Table 3
Cumulative toxicity.
| | | Patients | Cycles |
| | Number | 28 | 134 | | NCI-CTC Grade | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | | Nausea (%) | 10 (36) | 11 (39) | 2 (7) | — | 43 (32) | 18 (13) | 2 (1.5) | — | | Vomiting (%) | 7 (25) | 3 (11) | 2 (7) | — | 15 (11) | 5 (4) | 2 (1.5) | — | | Diarrhea (%) | 12 (43) | 8 (29) | 6 (21) | — | 48 (36) | 15 (11) | 7 (5) | — | | Hypoalbuminemia (%) | 1 (4) | 1 (4) | — | — | 1 (1) | 1 (1) | — | — | | Constipation (%) | 12 (43) | — | — | — | 16 (12) | — | — | — | | Stomatitis/mucositis (%) | 10 (36) | 1 (4) | 3 (11) | — | 19 (14) | 2 (1.5) | 3 (2) | — | | Erythema (%) | 2 (7) | — | 1 (4) | — | 2 (1.5) | — | 1 (1) | — | | Asthenia (%) | 9 (32) | 11 (39) | 3 (11) | — | 30 (22) | 23 (17) | 3 (2) | — | | Neurotoxicity (%) | 21 (75) | 4 (14) | — | — | 72 (54) | 4 (3) | — | — | | Hypertension (%) | 7 (25) | 3 (11) | — | — | 11 (8) | 3 (2) | — | — | | Hypotension (%) | 1 (4) | — | — | — | 1 (1) | — | — | — | | Hematuria (%) | — | 1 (4) | — | — | — | 1 (1) | — | — | | Gingival recession/gingivitis (%) | 5 (18) | — | — | — | 6 (4) | — | — | — | | Rhinitis (%) | 22 (78) | — | — | — | 50 (37) | — | — | — | | Epistaxis (%) | 20 (71) | — | — | — | 46 (34) | — | — | — | | HFS (%) | — | — | — | — | — | — | — | — | | Headache (%) | 5 (18) | — | — | — | 7 (5) | — | — | — | | Hypokalemia (%) | 2 (7) | — | — | — | 2 (1.5) | — | — | — | | Hypertransaminasemy (%) | 3 (11) | 1 (4) | — | 1 (4) | 5 (4) | 2 (1.5) | — | 1 (1) | | Hyperpigmentation (%) | 3 (11) | — | — | — | 5 (4) | — | — | — | | Fever without infection (%) | 6 (21) | — | — | — | 6 (4) | — | — | — | | Alopecia (%) | 3 (11) | 7 (25) | 3 (11) | — | 8 (6) | 14 (10) | 7 (5) | — | | Anemia (%) | 3 (11) | 2 (7) | — | — | 7 (5) | 2 (1.5) | — | — | | Leucopenia (%) | 10 (36) | 11 (39) | — | — | 34 (25) | 17 (13) | — | — | | Neutropenia (%) | 4 (14) | 11 (39) | 3 (11) | — | 25 (19) | 25 (19) | 3 (2) | — | | Thrombocytopeny (%) | 4 (14) | 1 (4) | — | — | 6 (4) | 1 (1) | — | — |
|
|
